Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies
- 28 June 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 97 (3) , 361-366
- https://doi.org/10.1111/j.1365-2249.1994.tb06095.x
Abstract
Recombinant virus-like particles (VLP), formed by the yeast Ty p1 protein, carrying the HIV gp120 V3 loop on their surface (V3-VLP) have been tested in vitro for immunogenicity and antigenicity by using VLP p1-specific human CD4+ T cell lines and clones. VLP-specific human T cell lines and clones were generated from normal individuals, indicating that VLP-specific precursor cells present in the peripheral lymphocyte pool can be induced to expand clonally upon antigen challenge in vitro, in the absence of previous immunization. It was also shown that V3-specific polyclonal antibodies enhance V3-VLP-induced activation of VLP-specific T cell clones. Antibody-dependent potentiation has been shown previously in other antigen systems, and it depends on enhanced uptake of complexed antigen by Fc receptor-positive antigen-presenting cells. Since in this case antigen is internalized by presenting cells as a complex, it can be inferred that a similar event of antibody-mediated antigen uptake can take place with V3-specific B cells, resulting in presentation by the B cells of T helper epitopes derived from processing of the VLP p1 moiety. This suggests that T helper cells specific for the carrier VLP p1 protein can be activated to provide help to V3-specific B cells in the presence of the appropriate antigen construct.Keywords
This publication has 57 references indexed in Scilit:
- Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccineThe Lancet, 1993
- Carrier sequence selection — one key to successful vaccinesImmunology Today, 1992
- Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.The Journal of Experimental Medicine, 1992
- A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1991
- Human Immunodeficiency Virus (HIV-l) gp160-Specific Lymphocyte Proliferative Responses of Mononuclear Leukocytes from HIV-l Recombinant gp160 Vaccine RecipientsThe Journal of Infectious Diseases, 1991
- Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 geneNature, 1991
- Receptor-Mediated Antigen Uptake and its Effect on Antigen Presentation to Class II-Restricted T LymphocytesAnnual Review of Immunology, 1990
- TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional PropertiesAnnual Review of Immunology, 1989
- T-cell strategies in AIDS vaccinesAIDS, 1989
- B cells on the podium: regulatory roles of surface and secreted immunoglobulinsImmunology Today, 1988